Top Bristol Biotech Companies (18)
Don't see your company?
Create a company profile
Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent the previously existing bio-design limits of conventional peptide synthesis with one universal process.
CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol. We’re working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world. Our mission is bold and ambitious and we have the best investors behind us from day 1. We’re backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We’re also supported by the founder/CEO of Abcam, which pioneered the antibody business.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.
Impulsonics is using the unique power of acoustics to make biotech automation simple and scalable so scientists can focus on the problems that matter.
A trusted partner at nearly three million customer locations, Ecolab (ECL) is the global leader in water, hygiene and infection prevention solutions and services. With annual sales of $12 billion and more than 44,000 associates, Ecolab delivers comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use, and improve operational efficiencies and sustainability for customers in the food, healthcare, hospitality and industrial markets in more than 170 countries around the world. For more Ecolab news and information, visit www.ecolab.com, or follow us on twitter.com/ecolab, facebook.com/ecolab or instagram.com/ecolab_inc.
GenomeKey enables targeted Sepsis treatment in hours, rather than days. This is important because Sepsis now kills more people than cancer. It can hit anyone, of any age, and kills within hours. A patient admitted to a hospital today, they wait 3 days before the doctor knows which antibiotic will fight the infection. We use cutting edge machine learning and DNA sequencing to bring 3 days down to just a few hours, with the only affordable test that provides a result for every patient. This saves lives, saves money, and saves our last antibiotics for when we really need them.
Our vision is to provide the world with the next-generation of therapeutics for unmet medical needs and future threats
Kelpi is a world-leading sustainable materials innovation business - harnessing the properties of seaweed to create compostable, marine-safe, low-carbon bioplastic packaging. We’re addressing the major problems of marine plastic pollution by replacing fossil fuel-plastics with materials that bio-degrade fully, leaving no toxins nor micro-plastics behind
The DeepTech Health Company
Ceryx Medical are an exciting new Medtech company developing a range of innovative bioelectronic devices. These devices use a unique chip technology which is able to mimic nerve centres within the body called central pattern generators. These CPGs help to control a range of autonomic or rhythmical processes such as peristalsis, heart rate and even walking. It is hoped that Ceryx’s artificial CPGs can restore normal performance where these processes have been affected by disease or injury.
Micrima was founded in 2005 to develop and commercialise microwave radar breast imaging technology initially pioneered at the University of Bristol in the UK. The company's MARIA system is currently in clinical trials to collect valuable data for our machine learning algorithm's. The latest step in the journey to Breast Screening will be launched in 2022. This new system will provide density information and improved ergonomics for patient and operator. Contact us to arrange to see this system or to find out more
Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, having many unique qualities compared to systemic administration of therapeutic protein, including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the tRBC, thereby shielding them from the immune system. Born out of more than a decade of research at the University of Bristol and its learnings from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells
Rosa Biotech is an AI-driven biosensing and diagnostics company based in Bristol. Our mission is to provide outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology. We have developed a novel sensing platform that leverages the rapid and precise approach honed over millions of years in the olfactory systems of mammals. By using machine learning we are capable of discriminating between complex biological samples and are able to predict commercial and clinical outcomes
Extracellular channels biology, digitalisation and biomanufacturing expertise to accelerate developments in biotech. We use our scale up experience and our deep insights into cellular behaviour to produce biomass for cultivated meat companies more efficiently. We're digitalising process development, pulling together huge quantities of data to make better decisions faster and at scale.
Stablepharma Ltd is an innovative biopharmaceutical company developing a range of next generation fridge-free vaccine products. Stablepharma was founded with a simple purpose; to use its novel technology to dramatically improve health outcomes for those adults and children most at risk of death and disability caused by vaccine preventable diseases. StablevaX is an adaptable fridge-free technology which offers an extended shelf-life, reduces vaccine wastage and the CO2 footprint of the cold-chain. The WHO estimate that approximately 50% of all vaccines manufactured are wasted due to failures in the global Cold Chain (distribution and storage of vaccines). Stablepharma aims to ensure that all vaccines can be removed from the refrigerated cold chain and stored for months or even years at room temperature. Stablepharma is developing the worlds first fridge-free vaccine, SPVX02 for Tetanus diphtheria, a speciality pharmaceutical product for the prevention of Tetanus and Diphtheria
CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.
eXmoor pharma is a one-stop cell and gene therapy partner accelerating the manufacturing journey from research to patients. Founded in 2004, eXmoor has specialized in the CGT sector since 2007 helping organisations to understand, plan and implement the appropriate CMC strategy. eXmoor does this via its translational and capital consulting groups, process and analytical development labs and now GMP manufacturing capability. eXmoor has completed over 500 projects for 150 clients and is headquartered in Bristol, UK, with 70 current employees, growing to 200 by 2027.
UK Biobank is a large-scale biomedical database and research resource containing genetic, lifestyle and health information from half a million UK participants. UK Biobank’s database, which includes blood samples, heart and brain scans and genetic data of the 500,000 volunteer participants, is globally accessible to approved researchers who are undertaking health-related research that’s in the public interest. UK Biobank recruited 500,000 people aged between 40-69 years in 2006-2010 from across the UK. With their consent, they provided detailed information about their lifestyle, physical measures and had blood, urine and saliva sample collected and stored for future analysis. UK Biobank’s research resource is a major contributor in the advancement of modern medicine and treatment, enabling better understanding of the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases and stroke. UK Biobank is generously supported by its founding funders the Wellcome Trust and UK Medical Research Council, as well as the Department of Health, Scottish Government, the Northwest Regional Development Agency, British Heart Foundation and Cancer Research UK. The organisation has over 150 dedicated members of staff, based in multiple locations across the UK.
Work Your Passion. Live Your Purpose.
